Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption (clinicaltrials.gov) - Oct 22, 2026 - P2 | N=191 | Not yet recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Trial completion date: Nov 2030 ➔ May 2033
Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4
|